Institut De Cancerologie De Bourgogne

At Institut De Cancerologie De Bourgogne in Dijon, a strong part of the portfolio focuses on neoplasms, especially breast cancer. These trials are studying HER2 positive, HR-positive, and triple-negative breast cancer with the goal of improving survival, lowering recurrence risk, and refining post-surgery treatment choices.

• Testing new treatment combinations for triple-negative breast cancer after surgery
• Evaluating therapies for HER2-positive and hormone receptor-positive early breast cancer
• Using ctDNA to better identify patients who may benefit from additional treatment

These studies aim to make breast cancer care more precise, with a focus on preventing relapse and improving long-term disease control.

The site also runs several studies in digestive system diseases, particularly colon cancer, rectal cancer, and colorectal cancer. The research is centered on improving outcomes after surgery, strengthening adjuvant treatment strategies, and exploring ways to better manage advanced or recurrent disease.

• Assessing treatment strategies for stage II and stage III colon cancer
• Studying new options for locally advanced rectal cancer and anal squamous cell carcinoma
• Testing approaches for metastatic colorectal cancer and advanced unresectable colorectal adenocarcinoma

These trials aim to improve disease-free survival, delay progression, and tailor therapy more closely to tumor risk and biology.

The oncology program includes important work in male urogenital diseases, especially prostate cancer. Trials are examining treatment for localized, high-risk, biochemical recurrent, and metastatic forms of the disease, with the goal of improving relapse control and reducing the spread of cancer.

• Evaluating treatment approaches for high-risk localized prostate cancer
• Studying options for biochemically recurrent prostate cancer
• Exploring therapy for oligometastatic and functionally imaged metastatic prostate cancer

Much of this research is focused on better controlling disease progression and identifying patients most likely to benefit from intensified treatment.

Another key area is hemic and lymphatic diseases, particularly multiple myeloma. The trials at this site are looking at ways to improve response rates, maintain remission after transplant, and strengthen long-term disease control in patients with relapsed or newly diagnosed disease.

• Testing new maintenance strategies after transplant in multiple myeloma
• Evaluating treatment effectiveness in relapsed or refractory myeloma
• Studying approaches aimed at deeper remission and better progression-free survival

These studies are designed to improve both the depth and durability of response for people living with blood cancers.

Smaller but notable efforts at the Institut De Cancerologie De Bourgogne include trials in oesophageal cancer, metastatic oeso-gastric adenocarcinoma, and rarer aggressive tumors such as neuroendocrine carcinoma. The overall aim is to improve treatment effectiveness in cancers that are often harder to treat.

• Assessing new combinations for unresectable oesophageal cancer
• Comparing treatment options in metastatic oeso-gastric adenocarcinoma
• Exploring better control strategies for high-grade neuroendocrine carcinoma

These research efforts focus on extending survival, improving disease control, and offering more effective options for patients with complex gastrointestinal cancers.